Cheap Tadalafil

In the first ever Canadian study measuring both patient and partner preference and satisfaction with erectile dysfunction (ED) treatments, Cialis® (tadalafil) was preferred over Viagra® (sildenafil).

In the study, both patients (58% to 70%) and their partners (65% to 75%) indicated that they preferred Cialis, after they either switched from sildenafil to Cialis or from Cialis to sildenafil. The findings were presented today at the 8th Congress of the European Society for Sexual Medicine in Copenhagen, Denmark.

Almost 2,800 Canadians Provide a ‘Real World’ Perspective
This study was designed to obtain data in a ‘real world’ clinical setting about treatment preference and satisfaction of both men and their partners when they switched from one treatment to another.

The study was conducted at 266 research sites across Canada and involved >2,600 patients who signed up and >2,400 patients and >320 partners who completed both visits. Patients who planned to change treatment from either sildenafil or Cialis to the other drug were invited to participate. Their level of satisfaction with their existing treatment was measured using the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire, both patient and partner versions, at their first physician visit.

Treatment preference by patients and their partners was measured at the second visit together with physician-rated patient preference. More than 98% of the patients completed the study.

While overall treatment satisfaction scores were higher for Cialis than sildenafil, the level of satisfaction was pronounced amongst partners, suggesting that the benefits of Cialis are particularly appealing to this group.

“In treatment of men with erectile dysfunction, the goal is to find a treatment that works well and, more importantly, satisfies both patients and their partners,” said Dr. Carrier, Urologist, CUSM-Royal Victoria Hospital. “This study may provide Canadian physicians with a stronger understanding of patient and partner preference and satisfaction levels. The information gained by these findings may assist physicians to help men and their partners find the treatment option that works best for them.”

Investors were pleased to see the first drops of black ink on Icos’ books in results reported Tuesday, but a predicted slowdown in sales growth this year contributed to a slide in after-hours trading.

Erectile-dysfunction drug Cialis had global sales of $747 million in 2005, a 35 percent increase over 2004. In December, the drug held a quarter of the U.S. market, up 5 percentage points from a year earlier. And costs for selling and marketing continued to decline.

These factors contributed to a $5.6 million fourth-quarter profit, the first in the Bothell company’s 15-year history.

But earnings of 9 cents a share, triple analysts’ expectations, didn’t distract investors from the company’s forecast that Cialis sales in 2006 will reach $860 million to $900 million, a growth rate of 15 to 20 percent.

The drug is sold through a joint venture with Eli Lilly.

Icos shares lost nearly 3 percent or 74 cents in after-hours trading Tuesday to settle at $23.99, according to The Associated Press.

“These guys just turned the corner to profitability, which is great, but I think still at this stage of the company, people are looking for top-line growth,” said Christopher Raymond, an analyst with Robert W. Baird & Co., which seeks investment-banking business with Icos.

Stock-option expenses in the range of $29 million to $31 million will contribute to a full-year 2006 net loss of $5 million to $25 million, Icos management said.

Had stock options been expensed in 2005, its net loss would have been $106.1 million.

Icos executives said they expect the market for erectile-dysfunction drugs to begin growing again this year, and they predict Cialis will continue gaining market share.

Married South Korean women are the least happy with their sex lives, according to the results of a survey of couples in South Korea, Japan, France and the United States.

The survey by the pharmaceutical firm Eli Lilly and Co, one of the makers of the anti-impotence drug Cialis, found the French had the best sex lives, followed by the Americans.

Fewer than one in three South Korean women said they were at least “slightly happy” about sex with their husbands, which was the lowest level of satisfaction among the four groups of women.

About half the surveyed South Korean men, however, said they were satisfied in bed with their wives.

“Not often enough” topped the list of complaints by men in all four countries while the main complaint of wives was not enough romance.

Fewer than one in three Japanese men said they would seek help for erectile dysfunction, the lowest number among the four groups of men, the survey said.

Fewer than one in 10 French men had any complaints about sex, which was the lowest level of dissatisfaction.